Objectives: To establish the prevalence and diversity of clinically significant extended-spectrum b-lactamase (ESBL)-producing Enterobacteriaceae harbouring bla CTX-M in the West Midlands region of the UK.
Introduction
The West Midlands region of the UK covers an area of 13000 km 2 , encompassing both large conurbations and remote rural areas, and has a population of 5.4 million. In 2003, a major outbreak of CTX-M-15-type, extended-spectrum b-lactamase (ESBL)-producing Escherichia coli belonging to the O25b-ST131 clone, and designated epidemic strain A by PFGE, was identified in Shrewsbury in the north-west of the region. 1 Conducted 3 years after the outbreak, this study aimed to establish the prevalence of this clone and other CTX-M-harbouring strains of Enterobacteriaceae in the West Midlands region using a structured survey. The study was carried out prospectively over a period of 2 months and included all new isolates of ESBL-producing Enterobacteriaceae from both community and hospitalized patients from the 13 major hospitals within the region. Isolates were fully characterized with respect to bla CTX-M , and two molecular typing methods, PFGE and PCR duplex detection of E. coli clone O25b-ST131, were used to assess the extent of clonality within CTX-M-producing isolates. This enabled the identification of possible shifts in the predominance of major clones and the emergence of new epidemic clones.
Methods
Bacterial isolates, ESBL screening and antimicrobial susceptibility testing organisms by local laboratory criteria, were collected from 13 hospitals in the West Midlands region of the UK. These isolates were obtained from both community and hospitalized patients. Community-acquired isolates were defined as those from patients who had not been hospitalized in the preceding 3 months; hospitalized patients whose first positive culture had been obtained .48 h after hospital admission were considered to have nosocomial infections. Organism identity was confirmed using API 20E (bioMérieux, Marcy-l'Étoile, France). All isolates were screened for susceptibility to cefpodoxime by the BSAC disc diffusion method (http://www.bsac.org.uk/Resources/BSAC/Ecoliklebsiella.pdf). ESBL production was confirmed phenotypically using cefpodoxime susceptibility, followed by ceftazidime and cefpirome+clavulanic acid double-disc diffusion. Antimicrobial susceptibility to a range of antimicrobial agents was also determined according to BSAC guidelines. Isolates were regarded as being multidrug resistant if they had reduced susceptibility to at least three structurally unrelated antibiotics.
PCR amplification
Confirmed ESBL-producing isolates were screened for the presence of bla CTX-M by our previously described multiplex PCR protocol. 2 Four sets of primers were used to amplify fragments of bla CTX-M open reading frames of CTX-M-type ESBLs, designed to give product sizes of 341 bp (group 2), 293 bp (group 9), 255 bp (group 1) and 207 bp (groups 25/ 26 and 8). Detection of insertion sequence (IS) IS26 was performed for all isolates carrying bla CTX-M using primers IS26F and IS26R, described previously. 1 
Denaturing HPLC (DHPLC) and sequencing
The bla CTX-M -positive isolates were further genotyped using the DHPLC method previously published by our group. 3 Representative control strains GZ3 (CTX-M-3), Y19 (CTX-M-9), J1 (Toho-1) and ESBL530 (CTX-M-25) were used as reference standards for groups 1, 9, 2 and 25/ 26, respectively. The chromatographic signatures of unknown bla CTX-M types were compared with the reference peaks. DHPLC genotyping results were confirmed by DNA sequencing of a limited number of isolates (30) from the study. PCR fragments covering the whole open reading frame of the relevant bla CTX-M gene were cleaned by using a QIAquick PCR purification kit (QIAGEN, Hilden, Germany). The PCR product was sequenced using an ABI BigDye Terminator (version 3.0) cycle sequencing kit and the sequences were analysed on an ABI 3700 DNA Analyzer.
PFGE and identification of the O25b-ST131 E. coli clone by PCR All bla CTX-M -positive E. coli and Klebsiella isolates were typed by PFGE (Bio-Rad Laboratories, Hemel Hempstead, UK) after the digestion of genomic DNA with XbaI. The PFGE banding patterns were analysed using BioNumerics software (Applied Maths, Sint-Martens-Latem, Belgium). The unweighted pair-group method using arithmetic averages was used to obtain a dendrogram. Isolates were considered clonally related if the Dice coefficient correlation was ≥85%. The duplex PCR method recently described by Clermont et al. 4 was employed to identify the O25b-ST131 E. coli clone using PCR primers O25pabBspe.F, O25pabB-spe.R, trpA.F and trpA2.R.
Results
Detection of bla CTX-M and IS elements, demographics, and epidemiology Three hundred and forty-five (93.2%) of the 370 isolates submitted were confirmed as ESBL producers. Multiplex PCR assay revealed that 294 (85.2%) of these carried bla CTX-M . The 294 bla CTX-M -positive isolates included 232 E. coli, 58 Klebsiella spp., 3 Enterobacter spp. and 1 Proteus vulgaris. One hundred and seventy-five (59.5%) originated from hospital patients and 119 (40.5%) originated from the community. The majority of these isolates were associated with urinary tract infections (241, 82.0%), but there were also 25 blood culture isolates (8.5%).
PCR amplification identified IS26 in 62 of the 294 (21%) bla CTX-M producers, with two fragments of 400 bp (43/62) and 873 bp (19/62). Two of each type of IS26 fragment were sequenced and no T to C change was found in the spacer region between ISEcp1 and bla CTX-M-15 (GenBank accession numbers GU732831 and GU732832). 1 The distribution of the two fragment types for E. coli is shown in Table 1 . Of the 58 Klebsiella spp., two produced the 400 bp fragment and six produced the 873 bp fragment.
Antimicrobial resistance pattern of bla CTX-M -producing isolates
Some 82% of isolates proved to be multidrug resistant. Of these, 93.4% were resistant to ciprofloxacin, 91.4% to trimethoprim and 52.4% to gentamicin. Over half of all isolates were resistant to all three antibiotics. In addition, nine isolates showed reduced susceptibility to carbapenems. Xu et al.
Molecular typing of bla CTX-M -producing isolates by DHPLC
Of the 294 bla CTX-M -producing isolates, 284 (96.6%) possessed genes encoding group 1 CTX-M enzymes and 6 harboured a bla CTX-M group 9 gene. Two bla CTX-M group 2 and two group 25/ 26 producers were also identified. DHPLC genotyping of group 1 isolates showed that all had bla CTX-M-15 profiles. Specific chromatographic signatures of bla CTX-M were also obtained for the group 9, 2 and 25/26 isolates (four bla CTX-M-14 , two bla CTX-M-9 , two bla CTX-M-2 and two bla CTX-M-26 ). DNA sequencing was performed on 30 (10%) representative DHPLC-typed strains producing bla CTX-M-15 , bla CTX-M-14 , bla CTX-M-9 , bla CTX-M-2 and bla CTX-M-26 .
Isolates were confirmed to possess bla CTX-M-15 , bla CTX-M-9 , bla CTX-M-2 , and three of four bla CTX-M-14 producers had sequences identical to those in GenBank. However, one CTX-M-14 enzyme had three silent mutations at nucleotide positions 372, 570 and 702, with an A to G change at position 372, and G to A substitution at positions 570 and 702 (GenBank accession number GU732835).
Clonality characterization of bla CTX-M producers by PFGE analysis and O25b-ST131 E. coli clone detection Molecular typing by PFGE was performed for both bla CTX-Mproducing E. coli and Klebsiella spp. PFGE banding patterns were obtained for 225 of the 232 E. coli and 52 of the 58 Klebsiella spp. isolates. A cluster was designated when isolates showed ≥85% similarity to PFGE profiles. These clusters consisted of 2-102 isolates. PFGE analysis revealed that 213/225 (95%) bla CTX-M -positive E. coli fell into 23 clusters (seven of them were found in at least five isolates) and were defined as clones designated arbitrarily as RE1-23 and the seven major clusters (RE1-7) are shown in Figure 1 . They were distributed between both hospital and community isolates [55% (118/213) and 45% (95/213), respectively]. The remaining 12 E. coli isolates presented unique banding patterns. Out of the 213 strains in these 23 clusters, 102 (48%) strains constituted the largest clone RE1 and shared the UK epidemic strain A PFGE profile; they were widely dispersed in 12 out of the 13 hospitals studied and all harboured bla CTX-M-15 , except for one, which carried bla CTX-M-9 . The second largest clonal group, RE2, accounted for 14.6% of the strains (31/213), of which 24 (77%) were hospital isolates. Clones RE16, 18 and 23 were each found at a single hospital. Duplex PCR on all 232 E. coli isolates revealed that 66% (154/ 232) were O25b-ST131 positive. Of these, all but two were resistant to ciprofloxacin; resistance to trimethoprim and gentamicin was found in 92.2% and 48.7%, respectively. The O25b-ST131 isolates were represented in 14 of the 23 PFGE clusters (RE1 -6, 8, 10, 12, 13, 16, 20, 22 and 23) and in two unique PFGE types (Figure 1 ). The majority of the strains in clones RE1 (99/102) and RE2 (25/31) were O25b-ST131 positive. In contrast, 9/10 isolates in the third largest clone, RE3, and 10/12 isolates with unique banding patterns were non-O25b-ST131. Of the eight isolates that did not harbour bla CTX-M-15 (four CTX-M-14, two CTX-M-9 and two CTX-M-2), only one CTX-M-9 producer belonged to O25b-ST131. The clinical and molecular characteristics of O25b-ST131 and non-O25b-ST131 isolates, including bla CTX-M and IS26 genotyping, are summarized in Table 1 . The geographical distribution of RE1 and O25b-ST131 clones is shown in Figure 2 .
PFGE analysis of 52 of the 58 typeable Klebsiella spp. identified 11 clusters (RK1-11) and a further 12 unique PFGE profile types. RK1 and RK2 included isolates from 5 out of 10 hospitals and represented 33% of the isolates; all were CTX-M-15 producers, apart from two strains, which harboured bla CTX-M-26 and originated from the same hospital.
Discussion
By the end of 2003, CTX-M ESBLs had become the foremost cause of resistance to third-generation cephalosporins in Enterobacteriaceae in all regions of the UK. 5 In comparison with the South-East regional survey of 2004, where CTX-M types accounted for 51% and 82% of ESBLs in E. coli and Klebsiella spp., respectively, 6 we found a significantly higher prevalence of bla CTX-M [89% (232/260) and 88% (58/66) for E. coli and Klebsiella spp., respectively]. This is consistent with recent reports from Ireland (89%), 7 China (89%), 8 Spain (86%) 9 and France (83%), 10 with the highest prevalence (96.6%) being documented in Thailand. 11 The distribution of predominant bla CTX-M genotypes varies geographically.
12 -15 CTX-M-15 is the dominant genotype worldwide, 16 -18 with the exception of South-East Asia, where CTX-M-14 is common. 19 In a national survey in 2004, Woodford et al.
1 identified an epidemic CTX-M-producing strain (strain A), which had caused a major outbreak in Shropshire, part of the West Midlands region. This survey, which included 42 centres nationally, found that strain A was confined to London and the South-East, Northern Ireland and the West Midlands, with 61.4% of all isolates originating from the single West Midlands site at the centre of the outbreak. 1 Our survey is the first prospective study to characterize all bla CTX-M -producing ESBL isolates in the West Midlands region. It was both large scale (294 CTX-M-producing isolates) and geographically comprehensive, reflecting the population distribution both in urban and rural areas (13 hospital laboratories).
Genotyping bla CTX-M by DHPLC revealed that CTX-M-15 is now the predominant CTX-M genotype across the region, providing evidence of its exceptionally successful dissemination in both community and hospital settings. The worldwide spread of bla CTX-M-15 -producing E. coli has been ascribed to the clonal expansion of a particularly virulent multidrug-resistant clonal group, O25b-ST131.
9,16,17 Indeed, all five major UK CTX-M-producing E. coli strains, including epidemic strain A identified in the 2004 national survey, 1 have been shown to be of the O25b-ST131 lineage. 20 Our study, carried out 3 years after the UK national survey, 1 revealed that E. coli isolates harbouring bla CTX-M-15 were present across the West Midlands region and were mainly clonal; the O25b-ST131 clone accounting for 66% of all the bla CTX-Mproducing E. coli isolates ( Table 1 ). The finding that nearly half of O25b-ST131 isolates were community acquired reinforces the suggestion that community-healthcare facilities could be a significant reservoir for this clone. 9 Significantly, almost all strains in the two largest PFGE clusters were members of the O25b-ST131 clonal group. The PFGE RE1 clone is indistinguishable from UK strain A, which caused a major outbreak in Shropshire in 2003. Despite the adoption of rigorous control measures, 5 our survey has shown that were identified with ≥85% similarity, which is marked by the vertical line. The arrow indicates the UK epidemic strain A, the reference strain used in this study.
the strain, which emerged at the beginning of 2003, not only persisted in Shropshire, but also spread to all but one (the most geographically remote) of the 13 other regional hospitals. Nevertheless, between these hospitals, prevalence varied markedly (10%-80%), even within a single conurbation (Figure 2 ). The reasons for this epidemiological variation are unknown, but may be related to population demographics.
Woodford et al. 1 demonstrated the universal insertion of a copy of IS26 into the ISEcp1 of plasmids carried by all strain A isolates, which yielded a 400 bp product in a PCR assay. In our study, only 37.3% (38/102) of strain A isolates produced a 400 bp IS26 fragment. We also found 3/130 non-strain A isolates to be positive for a 400 bp fragment. The IS26 400 bp fragment was found only in the O25b-ST131 lineage, but the carriage rate of that type of plasmid was much lower than previously reported. 21 This suggests that O25b-ST131 carries a more diverse collection of plasmids than can be assumed from the earlier study. 1 that four non-strain A isolates from a single centre with related PFGE patterns produced an IS26 fragment of 800 bp. We found 13 such E. coli strains, all but one of which belonged to the O25b-ST131 clone. Nine of these came from plasmids carried by strain A isolates and four were from non-strain A isolates. Of note, the isolates with an 873 bp IS26 product were from seven different centres across the region. These data suggest that plasmids carrying bla CTX-M-15 are more diverse than previously thought. Interestingly, the 873 bp IS26-bla CTX-M-15/-14 module has also been reported in India 21 (which has strong cultural links with the West Midlands) and Russia (GenBank accession number GQ385314). We found a similar configuration in six of our Klebsiella spp. There were only two previous reports in GenBank of the same configuration in Klebsiella spp. from Spain (GenBank accession number GQ845085) and Russia (GQ385315-7), suggesting that this arrangement may be involved in the mobilization of bla CTX-M into multiple species of Enterobacteriaceae .
In addition to the shared PFGE patterns, common serogroups and multilocus sequence typing (MLST) types, UK epidemic strain A was shown to be ciprofloxacin and trimethoprim resistant, but susceptible to gentamicin in accordance with the findings of Blanco et al.
9 from Spain. However, in our study of RE1 (strain A) clone isolates, susceptibility to gentamicin was seen in only 63.7%, despite co-resistance to ciprofloxacin and trimethoprim. A higher prevalence of resistance to gentamicin has also been described in Canada (86%) 22 and several geographically distant countries (50%). 16 Interestingly, all eight E. coli isolates harbouring non-bla CTX-M-15 were susceptible to gentamicin.
Recently, attention has been drawn to the O25b-ST131 clonal group, primarily due to its vital role in the clonal dispersal of CTX-M-15-producing ESBLs across the world. 16 O25b-ST131 exhibits a significantly more extensive virulence profile than those of comparably resistant non-clonal group isolates 16, 23 and its relative fitness may have contributed to its huge epidemiological success worldwide. Our study provides novel insights into the epidemiology of the dissemination and persistence of bla CTX-M-15 -producing O25b-ST131 in the West Midlands region of the UK. Whilst 154/ 232 bla CTX-M-15 -producing E. coli belonged to O25b-ST131, a significant number (78) of E. coli did not, and were represented by all but one of the 23 PFGE types and 10/12 unique profiles. This suggests that E. coli strains harbouring bla CTX-M-15 that are not part of the widespread O25b-ST131 clone are also capable of dissemination and persistence in patients.
In summary, our survey shows for the first time the great diversity of CTX-M-producing strains of Enterobacteriaceae that has developed within the West Midlands region of the UK within a 3 year period. While the predominant CTX-M-15-producing RE1 clone (strain A) has persisted for .3 years after its emergence and has spread throughout the region, not all isolates are of the O25b-ST131 lineage and not all possess IS26. In addition, this strain now shows increased resistance to gentamicin. The majority of RE1 strains do belong to the O25b-ST131 lineage, but this clone is also represented in 13 other PFGE types identified in the study, providing further evidence of its pivotal role in the dispersal of CTX-M-15-producing ESBLs. There was remarkable heterogeneity amongst the CTX-M-producing isolates that were neither strain A nor of the O25b-ST131 lineage, demonstrating the continuing potential for genetic diversification and emergence of new epidemic strains. While O25b-ST131 strains were more likely to originate in the community than in hospital (60:40), other strains were evenly distributed between the two. Interestingly, the CTX-M-26-producing strain of Klebsiella pneumoniae responsible for an outbreak in Birmingham in 2001 was not detected in this study. 24 
